<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01499511</url>
  </required_header>
  <id_info>
    <org_study_id>CRO1667</org_study_id>
    <secondary_id>2010-023875-24</secondary_id>
    <nct_id>NCT01499511</nct_id>
  </id_info>
  <brief_title>Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study</brief_title>
  <acronym>ASCOT-10</acronym>
  <official_title>Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ASCOT-10 is a follow-up study of surviving participants in the United Kingdom (UK)arm of the
      Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) which was conducted between 2000 and
      2005.ASCOT's results showed substantial cardiovascular benefit from: 1) the use of a
      cholesterol lowering drug (atorvastatin) compared to placebo, and 2) the use of a
      blood-pressure lowering strategy based on amlodipine when compared to a strategy based on
      atenolol. ASCOT-10 will test the hypothesis that the ASCOT subjects who originally received
      Atorvastatin and those who received amlodipine based treatment will continue to show a
      cardiovascular benefit relative to those who did not, even though all the subjects have had
      access to optimal treatment in the interim.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study investigators will have access to information about ASCOT patients from their study
      centre who have died since the end of the ASCOT study in 2005. Of the 8580 ASCOT patients
      from the United Kingdom, 7300 were flagged with The Information Centre for Health and Social
      Care at the end of the trial in 2005.This flagging process was re-activated in 2010 so that
      all deaths and incident cancers relating to these patients are now sent every three months to
      the ASCOT-10 co-ordinating centre. These results are identified by the ASCOT study number,
      with all personal data removed. These deceased patient numbers will be communicated to the
      participating sites so that the trial centre staff will not contact their families.

      An attempt will be made to contact all remaining patients from the participating UK ASCOT
      sites.

      Initial contact will be made via the general practitioner (GP) surgery. If the GP can provide
      up-to-date contact details and feels that it is appropriate to contact the patient, patients
      will then be sent an introductory letter, a patient information sheet, a consent form and a
      health questionnaire.

      They will be asked to complete a 'tick-box' form given the following options:

        1. Willing to complete health questionnaire.

        2. Willing for information about health to be given by GP or next of kin.

        3. Willing to give information by telephone only.

        4. Willing to attend study clinic for a single visit.

        5. Not willing to take part.

      They will be asked to complete this form, sign, date and return in a pre-paid envelope to
      their trial centre. This form will be used as the consent form for the questionnaire part of
      the study.

      They will also be asked to complete a simple health questionnaire. This will collect
      information on any health problems experienced since the end of the ASCOT trial (in
      particular about heart attacks and strokes/mini-strokes), as well as information on any
      hospital admissions during this period and current medication. In addition, information about
      current weight, exercise, alcohol consumption, smoking and general quality of life will be
      collected. Patients will be asked to return their completed questionnaire, along with their
      consent/reply form, to their local trial centre.

      If the study team have not received a response within four weeks, a further reminder letter
      will be sent. If no response has been obtained after a further four weeks, a final attempt
      will be made to contact the patient by letter or telephone call.

      10% of the study population from each trial centre, who will be chosen at random, will be
      invited to attend their trial centre for a single clinic visit. Further informed consent
      following discussion with member(s) of the study team will be obtained. During the clinic
      visit the questionnaire will be reviewed and several further measurements will be taken as
      follows:

        -  Blood pressure

        -  Weight

        -  Pulse wave analysis. (This is a simple, non-invasive test, very much like a blood
           pressure measurement, that gives us further information on the function of the heart and
           arteries)

        -  Blood for creatinine and estimated glomerular filtration rate(eGFR)(tests of kidney
           function), electrolytes (sodium and potassium), fasting lipids (cholesterol), fasting
           glucose, glycated haemoglobin (a further test for diabetes) An additional blood test
           will be taken and plasma stored for the later analysis of chemicals in the blood which
           might predict cardiovascular risk. Precise details of this further testing are not
           currently available. However, the plasma will be stored securely and no identifiable
           data will be present on the samples (i.e. they will be stored anonymously, identified
           only by the subject's study number).

      Every effort will be taken to contact patients who have moved since the ASCOT study closed
      and for whom no contact details are available. This may be done by health service tracking
      services, where available, or via Primary Care Trusts (PCTs).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2012</start_date>
  <completion_date type="Actual">January 31, 2016</completion_date>
  <primary_completion_date type="Actual">May 30, 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Have Died From Cardiovascular Disease Since the End of the ASCOT Study</measure>
    <time_frame>16 years</time_frame>
    <description>Number of participants who have died from cardiovascular disease since the end of the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Armstudy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Non Fatal Myocardial Infarction</measure>
    <time_frame>16 years</time_frame>
    <description>Morbidity of non fatal myocardial infarction after 16 years in patients recruited into the Anglo-Scandinavian Outcomes trial with two groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Non Fatal Stroke/TIA (Transient Ischaemic Attack)</measure>
    <time_frame>16 years</time_frame>
    <description>Non fatal stroke and TIA (Transient Ischaemic Attack) morbidity after 16 years in patients recruited into the Anglo-Scandinavian Outcomes trial</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Have Developed Diabetes Since the End of the ASCOT Trial</measure>
    <time_frame>16 years</time_frame>
    <description>Diabetes morbidity after 16 years in patients recruited into the Anglo-Scandinavian Outcomes trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Have Undergone Coronary/Peripheral Re-vascularisation Procedures Since the End of the ASCOT Trial</measure>
    <time_frame>16 years</time_frame>
    <description>Number of participants who have undergone coronary/peripheral re-vascularisation procedures since the end of the ASCOT trial, follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Have Required Renal Replacement Therapy (Dialysis or Kidney Transplant) Since the End of the ASCOT Trial</measure>
    <time_frame>16 years</time_frame>
    <description>Number of participants who have required renal replacement therapy (dialysis or kidney transplant) since the end of the ASCOT trial, follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Have Experienced a Transient Ischaemic Attack (TIA) Since the End of the ASCOT Trial</measure>
    <time_frame>16 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1718</enrollment>
  <condition>Hypertension</condition>
  <condition>Diabetes</condition>
  <condition>Death From Cardiovascular Disease</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>ASCOT participants amlodipine</arm_group_label>
    <description>It is follow up group from the ASCOT study, after treatment with amlodipine for 5.5 years. No treatment only follow up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASCOT participants atenolol</arm_group_label>
    <description>It is follow up group from the ASCOT study, after treatment with atenolol for 5.5 years. No treatment only follow up.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma to be stored for future measurement of biochemical markers of cardiovascular disease
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who participated in the Anglo-Scandinavian Cardiac Outcomes Trial in the UK
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Surviving ASCOT participants from the participating UK sites

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith A Mackay, MBBS PhD MRCP</last_name>
    <role>Study Director</role>
    <affiliation>Imperial College Healthcare NHS Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter S Sever, MBChB FRCP PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Simon M Thom, MBBS MD FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>International Centre for Circulatory Health</name>
      <address>
        <city>London</city>
        <zip>W2 1LA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Dahl√∂f B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005 Sep 10-16;366(9489):895-906.</citation>
    <PMID>16154016</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>February 7, 2011</study_first_submitted>
  <study_first_submitted_qc>December 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 26, 2011</study_first_posted>
  <results_first_submitted>July 4, 2019</results_first_submitted>
  <results_first_submitted_qc>November 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 3, 2019</results_first_posted>
  <last_update_submitted>November 13, 2019</last_update_submitted>
  <last_update_submitted_qc>November 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Mortality</keyword>
  <keyword>Morbidity</keyword>
  <keyword>Coronary Heart Disease</keyword>
  <keyword>Stroke</keyword>
  <keyword>Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ASCOT Participants Amlodipine</title>
          <description>It is follow up group from the ASCOT study, after treatment with amlodipine for 5.5 years. No treatment only follow up.</description>
        </group>
        <group group_id="P2">
          <title>ASCOT Participants Atenolol</title>
          <description>It is follow up group from the ASCOT study, after treatment with atenolol for 5.5 years. No treatment only follow up.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="885"/>
                <participants group_id="P2" count="833"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="884"/>
                <participants group_id="P2" count="833"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients recruited into long term follow up</population>
      <group_list>
        <group group_id="B1">
          <title>ASCOT Participants Amlodipine</title>
          <description>It is follow up group from the ASCOT study, after treatment with amlodipine for 5.5 years. No treatment only follow up.</description>
        </group>
        <group group_id="B2">
          <title>ASCOT Participants Atenolol</title>
          <description>It is follow up group from the ASCOT study, after treatment with atenolol for 5.5 years. No treatment only follow up.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="885"/>
            <count group_id="B2" value="833"/>
            <count group_id="B3" value="1718"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="173"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="800"/>
                    <measurement group_id="B2" value="745"/>
                    <measurement group_id="B3" value="1545"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75" lower_limit="54" upper_limit="93"/>
                    <measurement group_id="B2" value="74.5" lower_limit="52" upper_limit="91"/>
                    <measurement group_id="B3" value="74.8" lower_limit="52" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="739"/>
                    <measurement group_id="B2" value="720"/>
                    <measurement group_id="B3" value="1459"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="885"/>
                    <measurement group_id="B2" value="833"/>
                    <measurement group_id="B3" value="1718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Have Died From Cardiovascular Disease Since the End of the ASCOT Study</title>
        <description>Number of participants who have died from cardiovascular disease since the end of the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Armstudy</description>
        <time_frame>16 years</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>ASCOT Participants</title>
            <description>Participants from the ASCOT study recruited to the participating ASCOT study centres in the United Kingdom.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Have Died From Cardiovascular Disease Since the End of the ASCOT Study</title>
          <description>Number of participants who have died from cardiovascular disease since the end of the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Armstudy</description>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Non Fatal Myocardial Infarction</title>
        <description>Morbidity of non fatal myocardial infarction after 16 years in patients recruited into the Anglo-Scandinavian Outcomes trial with two groups</description>
        <time_frame>16 years</time_frame>
        <population>13 participants had missing data</population>
        <group_list>
          <group group_id="O1">
            <title>ASCOT Participants Amlodipine</title>
            <description>It is follow up group from the ASCOT study, after treatment with amlodipine for 5.5 years. No treatment only follow up.</description>
          </group>
          <group group_id="O2">
            <title>ASCOT Participants Atenolol</title>
            <description>It is follow up group from the ASCOT study, after treatment with atenolol for 5.5 years. No treatment only follow up.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Non Fatal Myocardial Infarction</title>
          <description>Morbidity of non fatal myocardial infarction after 16 years in patients recruited into the Anglo-Scandinavian Outcomes trial with two groups</description>
          <population>13 participants had missing data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="877"/>
                <count group_id="O2" value="828"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.624</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Non Fatal Stroke/TIA (Transient Ischaemic Attack)</title>
        <description>Non fatal stroke and TIA (Transient Ischaemic Attack) morbidity after 16 years in patients recruited into the Anglo-Scandinavian Outcomes trial</description>
        <time_frame>16 years</time_frame>
        <population>18 participants had missing data</population>
        <group_list>
          <group group_id="O1">
            <title>ASCOT Participants Amlodipine</title>
            <description>It is follow up group from the ASCOT study, after treatment with amlodipine for 5.5 years. No treatment only follow up.</description>
          </group>
          <group group_id="O2">
            <title>ASCOT Participants Atenolol</title>
            <description>It is follow up group from the ASCOT study, after treatment with atenolol for 5.5 years. No treatment only follow up.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Non Fatal Stroke/TIA (Transient Ischaemic Attack)</title>
          <description>Non fatal stroke and TIA (Transient Ischaemic Attack) morbidity after 16 years in patients recruited into the Anglo-Scandinavian Outcomes trial</description>
          <population>18 participants had missing data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="877"/>
                <count group_id="O2" value="823"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Have Developed Diabetes Since the End of the ASCOT Trial</title>
        <description>Diabetes morbidity after 16 years in patients recruited into the Anglo-Scandinavian Outcomes trial</description>
        <time_frame>16 years</time_frame>
        <population>22 participants had missing data</population>
        <group_list>
          <group group_id="O1">
            <title>ASCOT Participants Amlodipine</title>
            <description>It is follow up group from the ASCOT study, after treatment with amlodipine for 5.5 years. No treatment only follow up.</description>
          </group>
          <group group_id="O2">
            <title>ASCOT Participants Atenolol</title>
            <description>It is follow up group from the ASCOT study, after treatment with atenolol for 5.5 years. No treatment only follow up.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Have Developed Diabetes Since the End of the ASCOT Trial</title>
          <description>Diabetes morbidity after 16 years in patients recruited into the Anglo-Scandinavian Outcomes trial</description>
          <population>22 participants had missing data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="871"/>
                <count group_id="O2" value="825"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="322"/>
                    <measurement group_id="O2" value="325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.304</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Have Undergone Coronary/Peripheral Re-vascularisation Procedures Since the End of the ASCOT Trial</title>
        <description>Number of participants who have undergone coronary/peripheral re-vascularisation procedures since the end of the ASCOT trial, follow up</description>
        <time_frame>16 years</time_frame>
        <population>24 participants had missing data</population>
        <group_list>
          <group group_id="O1">
            <title>ASCOT Participants Amlodipine</title>
            <description>It is follow up group from the ASCOT study, after treatment with amlodipine for 5.5 years. No treatment only follow up.</description>
          </group>
          <group group_id="O2">
            <title>ASCOT Participants Atenolol</title>
            <description>It is follow up group from the ASCOT study, after treatment with atenolol for 5.5 years. No treatment only follow up.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Have Undergone Coronary/Peripheral Re-vascularisation Procedures Since the End of the ASCOT Trial</title>
          <description>Number of participants who have undergone coronary/peripheral re-vascularisation procedures since the end of the ASCOT trial, follow up</description>
          <population>24 participants had missing data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="872"/>
                <count group_id="O2" value="822"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.641</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Have Required Renal Replacement Therapy (Dialysis or Kidney Transplant) Since the End of the ASCOT Trial</title>
        <description>Number of participants who have required renal replacement therapy (dialysis or kidney transplant) since the end of the ASCOT trial, follow up</description>
        <time_frame>16 years</time_frame>
        <population>18 participants had missing data</population>
        <group_list>
          <group group_id="O1">
            <title>ASCOT Participants Amlodipine</title>
            <description>It is follow up group from the ASCOT study, after treatment with amlodipine for 5.5 years. No treatment only follow up.</description>
          </group>
          <group group_id="O2">
            <title>ASCOT Participants Atenolol</title>
            <description>It is follow up group from the ASCOT study, after treatment with atenolol for 5.5 years. No treatment only follow up.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Have Required Renal Replacement Therapy (Dialysis or Kidney Transplant) Since the End of the ASCOT Trial</title>
          <description>Number of participants who have required renal replacement therapy (dialysis or kidney transplant) since the end of the ASCOT trial, follow up</description>
          <population>18 participants had missing data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="874"/>
                <count group_id="O2" value="826"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.915</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Have Experienced a Transient Ischaemic Attack (TIA) Since the End of the ASCOT Trial</title>
        <time_frame>16 years</time_frame>
        <population>Combined together with 3. primary outcome, it was not possible to differentiate between data collected for TIAs and Non fatal stroke</population>
        <group_list>
          <group group_id="O1">
            <title>ASCOT Participants Amlodipine</title>
            <description>It is follow up group from the ASCOT study, after treatment with amlodipine for 5.5 years. No treatment only follow up.</description>
          </group>
          <group group_id="O2">
            <title>ASCOT Participants Atenolol</title>
            <description>It is follow up group from the ASCOT study, after treatment with atenolol for 5.5 years. No treatment only follow up.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Have Experienced a Transient Ischaemic Attack (TIA) Since the End of the ASCOT Trial</title>
          <population>Combined together with 3. primary outcome, it was not possible to differentiate between data collected for TIAs and Non fatal stroke</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ASCOT Participants Amlodipine</title>
          <description>Follow up study for amlodipine, no intervention.</description>
        </group>
        <group group_id="E2">
          <title>ASCOT Participants Atenolol</title>
          <description>Follow up study for atenolol, no intervention.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="885"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="833"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="885"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="833"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="885"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="833"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injuries</sub_title>
                <description>after fall from bicycle</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="885"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="833"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="885"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="833"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>High blood pressure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="885"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="833"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomach cramps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="885"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="833"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Collapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="885"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="833"/>
              </event>
              <event>
                <sub_title>Alcohol dependence withdrawal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="885"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="833"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="885"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="833"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Peter Sever</name_or_title>
      <organization>Imperial College London</organization>
      <phone>02075941100</phone>
      <email>p.sever@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

